ACP
MRSN

Acuta Capital Partners’s Mersana Therapeutics MRSN Stock Holding History

Acuta Capital Partners’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-44,820
Closed -$1.6M – 39
2024
Q4 		$1.6M Sell
44,820
-3,180
-7% -$165K 1.61% 21
2024
Q3 		$2.27M Sell
48,000
-18,520
-28% -$817K 1.84% 19
2024
Q2 		$3.34M Sell
66,520
-20,065
-23% -$1.45M 2.82% 15
2024
Q1 		$9.7M Sell
86,585
-8,135
-9% -$809K 6.3% 3
2023
Q4 		$5.49M Buy
94,720
+90,736
+2,278% +$3.65M 3.09% 14
2023
Q3 		$127K Buy
+3,984
New +$189K 0.08% 44
2023
Q2 		– Sell
-2,400
Closed -$247K – 39
2023
Q1 		$247K Sell
2,400
-35,600
-94% -$5M 0.18% 30
2022
Q4 		$5.57M Buy
+38,000
New +$6.42M 3.43% 13
2021
Q2 		– Sell
-14,308
Closed -$5.79M – 45
2021
Q1 		$5.79M Sell
14,308
-13,452
-48% -$6.52M 2.09% 20
2020
Q4 		$18.5M Buy
27,760
+1,060
+4% +$589K 5.03% 5
2020
Q3 		$12.4M Buy
26,700
+1,400
+6% +$707K 3.38% 8
2020
Q2 		$14.8M Sell
25,300
-7,800
-24% -$2.66M 4.28% 5
2020
Q1 		$4.82M Buy
+33,100
New +$5.78M 2.34% 17

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Acuta Capital Partners's MRSN Position: Q1 2025 in Review

Acuta Capital Partners sold out of Mersana Therapeutics (MRSN) in Q1 2025, closing a stake of 44,820 shares — an estimated $1.6M sold.

Acuta Capital Partners first reported a position in MRSN in Q1 2020 and held it in 13 quarters. The position peaked at $18.5M in Q4 2020. 108 funds tracked by Wall St. Rank hold MRSN as of Q1 2025.

  • Acuta Capital Partners reported no remaining Mersana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Acuta Capital Partners sold 44,820 Mersana Therapeutics shares in Q1 2025, an estimated $1.6M.
  • Acuta Capital Partners first reported a position in Mersana Therapeutics in Q1 2020 and held it in 13 quarters.
  • Acuta Capital Partners's Mersana Therapeutics position peaked at $18.5M in Q4 2020.
  • 108 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2025.

Based on Acuta Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.